Protumoral TSP50 regulates macrophage activities and polarization via production of TNF-α and IL-1β, and activation of the NF-κB signaling pathway

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Yang, Cheng ^a   Zhang, Dong Mei ^a   Song, Zhen Bo ^a   Hou, Ya Qin ^a   Bao, Yong Li ^a   Sun, Lu Guo ^a   Yu, Chun Lei ^a   Li, Yu Xin ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; ONCOPROTEIN; TESTES SPECIFIC PROTEASE 50; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL1B PROTEIN, MOUSE; SERINE PROTEINASE; TESTIS-SPECIFIC PROTEASE 50; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; CELL POLARITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HOMEOSTASIS; IMMUNOREGULATION; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PLASMID; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE HOMOLOGY; TUMOR MICROENVIRONMENT; ANIMAL; CELL LINE; CHO CELL LINE; CRICETULUS; CYTOLOGY; HUMAN; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CELL PROLIFERATION; CHO CELLS; CRICETULUS; HUMANS; INTERLEUKIN-1BETA; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; NF-KAPPA B; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84957071786     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145095     Document Type: Article

References (44)

1. Bachireddy P, Rakhra K, Felsher DW. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clinical and experimental immunology. 2012; 167 (2):188-94. doi: 10.1111/j.1365-2249.2011.04514.x ; PubMed Central PMCID: PMC3278684.
2. Shan J, Yuan L, Xiao Q, Chiorazzi N, Budman D, Teichberg S, et al. TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells. Cancer research. 2002; 62(1):290-4.
3. Yuan L, Shan J, De Risi D, Broome J, Lovecchio J, Gal D, et al. Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer. Cancer research. 1999; 59(13):3215-21.
4. Xu HP, Yuan L, Shan J, Feng H. Localization and expression of TSP50 protein in human and rodent testes. Urology. 2004; 64(4):826-32. doi: 10.1016/j.urology.2004.05.012.
5. Lei Zheng GX, Guangjie Duan, Xiaochu Yan, Qianwei Li. High Expression of Testes-Specific Protease 50 Is Associated with Poor Prognosis in Colorectal Carcinoma. PloS one. July 12, 2011;Volume 6 (Issue 7). doi: 10.1371/journal.pone.0022203.g001
6. Liu F, Cao Q, Liu N, Li C, You C, Liu C, et al. Overexpression of Testes-Specific Protease 50 (TSP50) Predicts Poor Prognosis in Patients with Gastric Cancer. Gastroenterology research and practice. 2014; 2014:498246. doi: 10.1155/2014/498246 ; PubMed Central PMCID: PMC3985325.
7. Song ZB, Bao YL, Zhang Y, Mi XG, Wu P, Wu Y, et al. Testes-specific protease 50 (TSP50) promotes cell proliferation through the activation of the nuclear factor kappaB (NF-kappaB) signalling pathway. Biochem J. 2011; 436(2):457-67. Epub 2011/03/10. doi: 10.1042/bj20101780.
8. Li YY, Bao YL, Song ZB, Sun LG, Wu P, Zhang Y, et al. The threonine protease activity of testes-specific protease 50 (TSP50) is essential for its function in cell proliferation. PloS one. 2012; 7(5):e35030. doi: 10.1371/journal.pone.0035030 ; PubMed Central PMCID: PMC3344824.
9. Zhang X. Depression of testes-specific protease 50 (TSP50) inhibits cell proliferation and induces apoptosis in laryngocarcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi: 10.1007/s13277-014-2090-y.
10. Zhou L, Bao YL, Zhang Y, Wu Y, Yu CL, Huang YX, et al. Knockdown of TSP50 inhibits cell proliferation and induces apoptosis in P19 cells. IUBMB life. 2010; 62(11):825-32. doi: 10.1002/iub.390.
11. Gattinoni L, Powell DJ Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nature reviews Immunology. 2006; 6(5):383-93. doi: 10.1038/nri1842 ; PubMed Central PMCID: PMC1473162.
12. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer research. 2012; 72(13):3125-30. doi: 10.1158/0008-5472.CAN-11-4094.
13. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nature reviews Neuroscience. 2011; 12(7):388-99. doi: 10.1038/nrn3053.
14. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. doi: 10.1016/j.cell.2010.03.014.
15. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nature reviews Immunology. 2008; 8(12):958-69. doi: 10.1038/nri2448 ; PubMed Central PMCID: PMC2724991.
16. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clinical & developmental immunology. 2012; 2012:948098. doi: 10.1155/ 2012/948098 ; PubMed Central PMCID: PMC3385963.
17. Sironi M, Martinez FO, D'Ambrosio D, Gattorno M, Polentarutti N, Locati M, et al. Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). Journal of leukocyte biology. 2006; 80(2):342-9. doi: 10.1189/jlb.1005586.
18. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in immunology. 2002; 23(11):549-55.
19. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25(12):677-86. Epub 2004/ 11/09. doi: 10.1016/j.it.2004.09.015.
20. Ning BT, Tang YM. Establishment of the cell line, HeLa-CD14, transfected with the human CD14 gene. Oncology letters. 2012; 3(4):871-4. doi: 10.3892/ol.2012.557 ; PubMed Central PMCID: PMC3362372.
21. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer research. 2004; 64(10):3365-70. doi: 10. 1158/0008-5472.CAN-03-2682.
22. Xie X, Zou G, Li C. Antitumor and immunomodulatory activities of a water-soluble polysaccharide from Chaenomeles speciosa. Carbohydrate polymers. 2015; 132:323-9. doi: 10.1016/j.carbpol.2015.06. 046.
23. Ngo AN, Ezoulin MJ, Youm I, Youan BB. Optimal Concentration of 2, 2, 2-Trichloroacetic Acid for Protein Precipitation Based on Response Surface Methodology. Journal of analytical & bioanalytical techniques. 2014; 5(4). doi: 10.4172/2155-9872.1000198 ; PubMed Central PMCID: PMC4351878.
24. Asai A, Nakamura K, Kobayashi M, Herndon DN, Suzuki F. CCL1 released from M2b macrophages is essentially required for the maintenance of their properties. Journal of leukocyte biology. 2012; 92 (4):859-67. doi: 10.1189/jlb.0212107.
25. Dalrymple H, Barna BP, Malur A, Malur AG, Kavuru MS, Thomassen MJ. Alveolar macrophages of GM-CSF knockout mice exhibit mixed M1 and M2 phenotypes. BMC Immunol. 2013; 14:41. doi: 10. 1186/1471-2172-14-41 ; PubMed Central PMCID: PMC3848434.
26. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(41):14825-30. doi: 10.1073/ pnas.0503039102 ; PubMed Central PMCID: PMC1253545.
27. Balkwill F, Joffroy C. TNF: a tumor-suppressing factor or a tumor-promoting factor? Future oncology. 2010; 6(12):1833-6. doi: 10.2217/fon.10.155.
28. Saperstein S, Chen L, Oakes D, Pryhuber G, Finkelstein J. IL-1beta augments TNF-alpha-mediated inflammatory responses from lung epithelial cells. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2009; 29(5):273-84. doi: 10. 1089/jir.2008.0076 ; PubMed Central PMCID: PMC2718541.
29. Kida Y, Kobayashi M, Suzuki T, Takeshita A, Okamatsu Y, Hanazawa S, et al. Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. Cytokine. 2005; 29(4):159-68. doi: 10.1016/j.cyto.2004. 10.009.
30. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer cell. 2010; 18(5):485-98. doi: 10.1016/j.ccr.2010.10.002 ; PubMed Central PMCID: PMC2991103.
31. Li Y, Casey SC, Felsher DW. Inactivation of MYC reverses tumorigenesis. Journal of internal medicine. 2014; 276(1):52-60. doi: 10.1111/joim.12237 ; PubMed Central PMCID: PMC4065197.
32. Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer metastasis reviews. 2006; 25(3):307-13. doi: 10.1007/s10555-006-9000-8.
33. Liu J, Song B, Wang JL, Li ZJ, Li WH, Wang ZH. Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer. World journal of gastroenterology: WJG. 2011; 17(10):1362-7. doi: 10.3748/wjg.v17.i10.1362 ; PubMed Central PMCID: PMC3068274.
34. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunologic research. 2011; 51(2-3):170-82. doi: 10.1007/s12026-011-8262-6.
35. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, et al. M2 Macrophages Phagocytose Rituximab- Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro. The Journal of Immunology. 2009; 182(7):4415-22. doi: 10.4049/jimmunol.0713732
36. Keophiphath M, Rouault C, Divoux A, Clement K, Lacasa D. CCL5 promotes macrophage recruitment and survival in human adipose tissue. Arteriosclerosis, thrombosis, and vascular biology. 2010; 30 (1):39-45. doi: 10.1161/ATVBAHA.109.197442.
37. Bai J, Adriani G, Dang TM, Tu TY, Penny HL, Wong SC, et al. Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and beta2 integrin interactions. Oncotarget. 2015.
38. Zhang B, Bailey WM, Braun KJ, Gensel JC. Age decreases macrophage IL-10 expression: Implications for functional recovery and tissue repair in spinal cord injury. Experimental neurology. 2015; 273:83-91 doi: 10.1016/j.expneurol.2015.08.001.
39. Ortiz MC, Lefimil C, Rodas PI, Vernal R, Lopez M, Acuna-Castillo C, et al. Neisseria gonorrhoeae Modulates Immunity by Polarizing Human Macrophages to a M2 Profile. PloS one. 2015; 10(6):e0130713. doi: 10.1371/journal.pone.0130713 ; PubMed Central PMCID: PMC4488386.
40. Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Monkkonen J, et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast cancer research: BCR. 2015; 17 (1):101. doi: 10.1186/s13058-015-0621-0 ; PubMed Central PMCID: PMC4531540.
41. Xu H, Shan J, Jurukovski V, Yuan L, Li J, Tian K. TSP50 encodes a testis-specific protease and is negatively regulated by p53. Cancer research. 2007; 67(3):1239-45. doi: 10.1158/0008-5472.CAN-06- 3688.
42. Pagliari LJ, Perlman H, Liu H, Pope RM. Macrophages require constitutive NF-kappaB activation to maintain A1 expression and mitochondrial homeostasis. Molecular and cellular biology. 2000; 20 (23):8855-65. ; PubMed Central PMCID: PMC116114.
43. Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. International journal of biological sciences. 2014; 10(5):520-9. doi: 10.7150/ijbs.8879 ; PubMed Central PMCID: PMC4046879.
44. Heuff G, Oldenburg HS, Boutkan H, Visser JJ, Beelen RH, Van Rooijen N, et al. Enhanced tumour growth in the rat liver after selective elimination of Kupffer cells. Cancer immunology, immunotherapy: CII. 1993; 37(2):125-30.